Patents Assigned to Merck
  • TN and STN liquid-crystal displays
    Publication number: 20020064607
    Abstract: The invention relates to TN and STN liquid-crystal displays and to the novel nematic liquid-crystal mixtures used therein, characterized in that they comprise one or more compounds of the formula I 1
    Type: Application
    Filed: June 19, 2001
    Publication date: May 30, 2002
    Applicant: Merck Patent GmbH
    Inventors: Harald Hirschmann, Martina Weidner, Sven Schupfer, Peer Kirsch
  • HIV integrase inhibitors
    Patent number: 6395743
    Abstract: Compounds useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines are described. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. The culture Actinoplanes sp. MA7220 (ATCC 202188) is also disclosed, as well as processes for making compounds of the present invention employing the culture.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: May 28, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Brian Heimbuch, Sheo Singh, Deborah L. Zink, Magda Gagliardi, Olga Genilloud, Ana Teran
  • Thin porous layers for thin-layer chromatography
    Patent number: 6395178
    Abstract: Novel separation materials for thin layer chromatography are disclosed; these consist of a support and a separation medium layer and are obtainable by the following process steps: a) cleaning of the support; b) application of a liquid film comprising a polysilicic ester to a support; c) introduction of the support with the liquid film into an atmosphere which effects hydrolysis and further polymerization of the polysilicic ester; d) hydrolysis and further polymerization of the polysilicic ester at constant temperature; e) washing of the silica layer; f) drying of the silica layer. The silica gel surface of the separation material of the invention can be modified by means of separation effectors.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: May 28, 2002
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Heinz-Emil Hauck, Rolf Eymann, Günther Sättler
  • Methods of identifying modulators of a DP prostaglandin receptor
    Patent number: 6395499
    Abstract: A human prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the human prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: June 20, 2000
    Date of Patent: May 28, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Kathleen Metters, Yves Boie, Nicole Sawyer, Deborah M. Slipetz
  • Process for the preparation of vinylene carbonate, and the use thereof
    Patent number: 6395908
    Abstract: The invention relates to a process for the preparation of vinylene carbonate of the formula (I) by reacting a monohaloethylene carbonate of the formula (II) in which X is a halogen atom, with a dehydrohalogenating agent at elevated temperature in the presence of an organic solvent, characterized in that the organic solvent employed is ethylene carbonate. The process according to the invention enables vinylene carbonate to be prepared in a simple manner and in high yield. The vinylene carbonate prepared in accordance with the invention can be used for various applications.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: May 28, 2002
    Assignee: Merck Patentgesellschaft
    Inventors: Bernhard Seifert, Sylvia Becker, Mark Neuschütz
  • Tetrahydroindolone derivatives as gabaaalpha5 ligands for enhancing cognition
    Patent number: 6395766
    Abstract: Compounds according to Formula (I) or a pharmaceutically acceptable salt thereof are GABA-A Alpha 5 ligands useful for enhancing cognition: where A is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, arylC1-6alkyl, or aryl wherein the aryl group is optionally substituted by halogen, C1-6alkyl, CF3, CN, NO2 or NH2, NR1R10, S(O)pR1, heteroarylC1-6alkyl or heteroaryl where heteroaryl is a 5- or 6-membered heteroaromatic ring as defined for B; and B is phenyl or a 5-membered ring having one or two unsaturations containing 1, 2, 3, or 4 heteroatoms chosen from O, N and S provided that not more than one heteroatom is other than N, a 6-membered heteroaromatic ring containing 1, 2, 3 or 4 nitrogen atoms, each of which rings is optionally substituted by one or more substituents.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: May 28, 2002
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Howard Barff Broughton, Helen Jane Bryant, Mark Stuart Chambers, Neil Roy Curtis
  • Tetrahydroindazole derivatives as ligands for GABA-A &agr; 5 receptors
    Patent number: 6395905
    Abstract: 4-oxo-tetrahydroindozole-3-carboxamide compounds according to Formula (I), or a pharmaceutically acceptable salt thereof, are GABA-A Alpha 5 ligands useful for enhancing cognition:
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: May 28, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Helen Jane Bryant, Mark Stuart Chambers
  • Cleavage system inhibitors as potential antipsychotics
    Patent number: 6395780
    Abstract: The invention relates to inhibitors of the glycine cleavage system and their use as potential antipsychotic agents. The invention relates furthermore to a process for treating humans having psychosis, psychosis associated with an illness, schizophrenia, Alzheimers disease or other related psychotic disorders.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: May 28, 2002
    Assignee: Merck Patent GmbH
    Inventors: Michael Arlt, Gerd Bartoszyk
  • Trans-glycosidation process for the synthesis of (2R, 2-alpha-R, 3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine
    Patent number: 6395898
    Abstract: The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: May 28, 2002
    Assignee: Merck & Co. Inc.
    Inventors: James M. McNamara, Matthew M. Zhao
  • Adenoviral based promoter assay
    Patent number: 6395473
    Abstract: Adenoviral vectors are used to transfer a promoter/reporter gene construct to mammalian cell cultures. The promoter/reporter gene construct is used to determine if a candidate inducing agent has promoter-inducing activity; or can be used to determine if a candidate promoter has activity in the presence of a known inducer.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: May 28, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Karen Richards, Thomas H. Rushmore, Manal A. Morsy
  • Process for producing an accumulator composite for accumulating heat or cold
    Publication number: 20020060063
    Abstract: The invention relates to a process for producing an accumulator composite comprising evacuating an impregnation vessel after partially or completely immersing a matrix in a phase change material in the impregnation vessel.
    Type: Application
    Filed: May 15, 2001
    Publication date: May 23, 2002
    Applicant: Merck GmbH
    Inventors: Mark Neuschutz, Marlies Niemann
  • Electrooptical system
    Publication number: 20020060761
    Abstract: The invention relates to an electrooptical system according to the preamble of claim 1, where the angle &psgr;, which the polarization device forms on the input side with the directors of the liquid-crystal molecules on the 1st substrate surface, is optimized in order to achieve high contrast and/or high brightness and/or high viewing angle independence and/or the color values.
    Type: Application
    Filed: July 23, 2001
    Publication date: May 23, 2002
    Applicant: Merck Patent GmbH
    Inventors: Bernhard Scheuble, Gunter Baur, Waltraud Fehrenbach, Barbara Staudacher
  • Liquid-crystalline medium
    Publication number: 20020061368
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having positive dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I 1
    Type: Application
    Filed: November 2, 2001
    Publication date: May 23, 2002
    Applicant: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Kazuaki Tarumi, Brigitte Schuler, Eike Poetsch, Volker Reiffenrath, Yukiomi Tanaka
  • Liquid-crystalline medium
    Publication number: 20020060311
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having positive dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I 1
    Type: Application
    Filed: November 2, 2001
    Publication date: May 23, 2002
    Applicant: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Kazuaki Tarumi, Brigitte Schuler, Eike Poetsch, Volker Reiffenrath, Yukiomi Tanaka
  • Conjugates useful in the treatment of prostate cancer
    Patent number: 6391305
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA), hydrophilic oligopeptide blocking groups and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Grant
    Filed: June 28, 1999
    Date of Patent: May 21, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Dong-Mei Feng, Victor M. Garsky, Raymond E. Jones, Allen I. Oliff, Jenny M. Wai
  • Pigment preparation and its use especially in printing inks
    Publication number: 20020056399
    Abstract: The present invention relates to a pigment preparation comprising a mixture of coated and/or uncoated SiO2 flakes, one or more special-effect pigments, and a phosphate derivative, and to the use thereof, especially in printing inks.
    Type: Application
    Filed: October 19, 2001
    Publication date: May 16, 2002
    Applicant: Merck Patent GmbH
    Inventors: Sabine Schoen, Reiner Vogt, Norbert Schul, Karl Osterried, Gerhard Herget
  • Process for the synthesis of (2S)-phenyl-3-piperidone
    Patent number: 6388083
    Abstract: The present invention is concerned with novel processes for the preparation of (2S)-phenyl-3-piperidone. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Jaemoon Lee, David Askin, Thoa Hoang
  • DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof
    Patent number: 6387695
    Abstract: The present invention relates to nucleic acid formulations of pharmaceutical products which comprise citrate and/or triethanolamine in concentrations which enhance stability of the nucleic acid. These formulations are suited for situations where prolonged storage occurs during the distribution and/or storage period prior to use.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Evans, David B. Volkin, Mark W. Bruner, Zheng Xu
  • Pyrazinone thrombin inhibitors
    Patent number: 6387911
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein A is
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Christopher Burgey, Richard C. Isaacs, Bruce D. Dorsey, Kyle A. Robinson, Donnette Staas, Philip E. Sanderson, James Barrow
  • Somatostatin agonists
    Patent number: 6387932
    Abstract: This invention relates to non-peptide somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. The compounds provide an improved therapeutic index in the treatment of diabetes, cancer, acromegaly and retenosis. Many of the compounds are orally active.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Changyou Zhou, Alexander Pasternak, Gregori Morriello, Liangqin Guo, Yanping Pan, Lihu Yang, Arthur Patchett